Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
Asymmetric Reduction of<i>tert</i>-Butanesulfinyl Ketimines by N-Heterocyclic Carbene Boranes
作者:Tao Liu、Ling-yan Chen、Zhihua Sun
DOI:10.1021/acs.joc.5b02084
日期:2015.11.20
N-heterocycliccarbeneborane (NHC-borane) based on a triazole core is demonstrated for the first time to be efficient for reduction of a variety of tert-butanesulfinyl ketimines. Up to 95% yield and up to >99% diastereomeric excess were achieved. NHC-borane exhibited excellent activities that are more efficient than or comparable to commonly used reductive reagents such as NaBH4, NaBH3CN, l-selectride
2-Pyridylsulfinamides as effective catalysts in the asymmetric alkylation of aldehydes with diethylzinc
作者:Kavirayani R. Prasad、Omkar Revu
DOI:10.1016/j.tet.2013.07.061
日期:2013.9
Chiral 2-pyridylsulfinamides were shown to be effective catalysts in the alkylation of aryl and alkyl aldehydes with diethylzinc providing the corresponding alcohols in excellent enantioselectivity. Sulfinamide catalysts possessing solitary chirality at the sulfur center produced the product phenethyl alcohol in good enantioselectivity. Diastereomeric sulfinamides possessing chirality at the carbon-bearing nitrogen and at the sulfur of the sulfinamide increased the enantioselectivity of the product alcohols up to >99%. However, there is no effect of the match-mismatch pair of sulfinamide diastereomers on the outcome of the chiral induction of the product phenethyl alcohols. It was conclusively proved that chirality at the sulfur center is mandatory for obtaining good enantioselectivity in the reaction. (C) 2013 Elsevier Ltd. All rights reserved.
[EN] HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'ANTAGONISTES DE L'ADÉNOSINE
申请人:NUVATION BIO INC
公开号:WO2020150674A1
公开(公告)日:2020-07-23
Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.